ClinicalTrials.gg
TerminatedNCT05009953Updated Jul 11, 2024

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

A Phase 2 interventional study of Irinotecan Liposome Injection and SG001 in Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma and Extrahepatic Cholangiocarcinoma, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Internal strategy change. Not related to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Cholangiocarcinoma with a site in China — 114 open to participants now, 125 under way, 12 of them phase 3. Cholangiocarcinoma · China.

Enrollment
178th of 191
17 · median 51
Started
2021
with 14 others
Phase 2
100 of 230
53 open now
Registered
88th of 230
by date

Among the 230 studies in Cholangiocarcinoma with a site in China, this one is the 178th largest by enrollment of the 191 interventional ones that give a count, is one of 15 that started in 2021, is one of 100 in phase 2, and was the 88th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

114 of the 230 studies in Cholangiocarcinoma with a site in China are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cholangiocarcinoma with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, phase II study of irinotecan liposome injection in patients with advanced biliary tract cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan liposome injection in patients with advanced biliary tract cancer.

Read the detailed description

This is an open-label, parallel, multicentre, phase II study to evaluate the efficacy and safety of irinotecan liposome injection. Eligible patients will be divided into two cohorts according to the criteria for the corresponding cohort. The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV). The patients in cohort 2 will receive irinotecan liposome injection combined with a PD-1 inhibitor, 5-Fluorouracil and Leucovorin.

03

Conditions studied

  • Advanced Biliary Tract Cancer
  • Intrahepatic Cholangiocarcinoma
  • Extrahepatic Cholangiocarcinoma
  • Gallbladder Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. At least 18 years of age, regardless of gender. 2. or cytologically confirmed unresectable, locally advanced, or adenocarcinoma of biliary tract, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBC).

      3.At least one according to 1.1. 4.Previous standard system chemotherapy failed. First-line standard chemotherapy is defined as gemcitabine combined with capecitabine or platinum.

      5.Patients with prior local treatment (embolization, chemoembolization, radiofrequency ablation, or radical radiotherapy) must be completed at least 4 weeks before the first administration of the study drug, palliative decompensated radiotherapy (such as bone metastases) must be completed at least 2 weeks before the first administration of the study drug.

      6. (ECOG) performance status 0 to 1. 7. >3 months. 8.Adverse reactions must recover to grade 1 or baseline according to 5.0 (except for toxicity such as alopecia, grade 2 or less sensory neuropathy, etc., which have been judged no safety risk by investigators).

      9.Patients should not receive cell growth factors or blood and transfusion within 7 days before the initiate administration of study drug, and laboratory test should meet the following criteria: neutrophile count ≥1.5×10\^9/L;platelet count ≥90×10\^9/L; ≥90 g/L or ≥5.6 mmol/L;serum creatinine ≤1.5× or rate must be ≥ 50 mL/min when serum creatinine >1.0×ULN;total ≤1.5×ULN; (AST) and alanine aminotransferase (ALT) ≤2.5×ULN or ≤2.5×ULN if intrahepatic lesions exist;Albumin ≥3 g/dL.

      1. (APTT), International Normalized Ratio (INR) and prothrombin time (PT) ≤1.5 × ULN for patients not receiving therapeutic anticoagulation.

      11.Patients with biliary obstruction or no evidence of persistent infection should receive adequate biliary drainage; active or suspected infections are not allowed.

      1. Female patients with must agree to use adequate from the signing of to at least 6 months after the study completion and have a negative serum pregnancy test within 7 days before enrollment, and must be non-lactating. Male patients must agree to use medically approved contraception during the study and for 6 months after the study period.
      1. Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

Exclusion Criteria:

    1. Patients with definite positive NTRK fusion gene. 2. Patients who have received any drug within 4 weeks prior to the first dose of irinotecan liposomes injection.

      1. Patients with definite encephalopathy. 4. Patients who have received liver transplantation or liver metastases accounted for 50% or more of the total liver volume.
      1. Patients with hepatic encephalopathy. 6. Uncontrolled third lacunar effusion other than ascites (e.g., large pleural or pericardial effusion).
      1. Previous in the past five years (except radically resected and non-recurring basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, local prostate carcinoma, carcinoma in situ of cervical, or other carcinoma in situ).
      1. History of serious cardiovascular disease. 9. Patients with uncontrolled active bleeding. 10. Gastrointestinal diseases of clinical significance, such as bleeding, inflammation, obstruction, >grade 1 diarrhea, etc.
      1. Patients with definite Gilbert syndrome. 12. Patients who have concomitant use of strong inducers within 2 weeks prior to the first dose, or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 1 week prior to the first dose.
      1. Patients who received systemic or other agents within 14 days before the first dose of the study drug.
      1. Patients who have undergone major organ surgery within 4 weeks prior to the first dose of the study drug.
      1. Patients who are to any component of irinotecan liposome injection or other liposome products.
      1. Patients who are allergic to gemcitabine, cisplatin, fluorouracil or leucovorin or its components.

Additional exclusion criteria for cohort 2:

  1. Patients who have received any other antibodies or drugs that act on T-cell synergetic stimulation or checkpoint pathways (including , PD-L1, CTLA-4 inhibitors, etc.).
  2. Patients with a history of severe allergic reactions to monoclonal antibodies and uncontrolled allergic asthma.
  3. Patients with active disease or a history of autoimmune diseases.
  4. History of primary immunodeficiency.
  5. Patients who occurred immune related adverse events.
  6. History of allogeneic organ or hematopoietic stem cell transplantation.
  7. Received within 14 days before screening period or planned to received it during the study period.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Cohort 1: Irinotecan Liposome Injection + 5-FU/LV

    The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.

    Drug: Irinotecan Liposome Injection · Drug: Fluorouracil · Drug: Leucovorin

  • Experimental
    Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV

    The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.

    Drug: Irinotecan Liposome Injection · Drug: SG001 · Drug: Fluorouracil · Drug: Leucovorin

Interventions

  • Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL

  • DrugSG001

    Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL

  • 5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle

  • Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The percentage of patients who achieve a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    Time frame: Up to six months after the last patient's first administration

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time from date of the first dose to date of recorded disease progression or death, whichever occurs first

    Time frame: Up to six months after the last patient's first administration

  2. Overall survival (OS)

    Time from date of the first dose to date of death from any cause

    Time frame: Up to six months after the last patient's first administration

  3. Disease Control Rate (DCR)

    The percentage of patients who achieve a CR, PR or stable disease (SD) based on the RECIST 1.1

    Time frame: Up to six months after the last patient's first administration

  4. Duration of Response (DOR)

    Time from first documented response (CR or PR whichever occurs first, based on investigator's assessment per RECIST 1.1) to date of disease progression or death due to any cause, whichever occurs first

    Time frame: Up to six months after the last patient's first administration

  5. Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)

    The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0

    Time frame: Up to six months after the last patient's first administration

  6. Peak Plasma Concentration

    Cmax

    Time frame: 0-240 h of circle 1 to circle 4

  7. Area under the plasma concentration versus time curve

    AUC

    Time frame: 0-240 h of circle 1 to circle 4

  8. UGT1A1

    UGT1A1 gene polymorphism

    Time frame: Within 3 days before the first dose

07

Study locations

1 site
  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 18, 2021
StartActual
Sep 1, 2021
Primary completionActual
Jan 16, 2023
CompletionActual
Jan 16, 2023
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05009953
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Sep 1, 2021
Primary completion
Jan 16, 2023
Completion
Jan 16, 2023
Last update
Jul 11, 2024

Study contacts

Xiangdong Cheng
principal investigator · Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion